The core of Gertjan Kuipers' practice is patent law, where his background in science serves him well. His practice cuts across all fields of technology, including pharmaceutical, chemical electrical, mechanical and computer technology.

Gertjan advises and litigates for a number of national and international companies. Most of Gertjan’s work is cross-border in nature and he has extensive experience in conducting and coordinating multi-jurisdictional litigation. Gertjan was lead counsel in the widely reported Senseo coffee pad cases dealing with the concept of indirect patent infringement in which he worked with and coordinated the work of IP firms in four European countries (Sara Lee/DE v Coffee pad producers). In the pharmaceutical and food area, Gertjan acts for an international specialised nutrition company on patent litigation involving food additives. He also acted for Pfizer in the Viagra® litigation. 

In addition to patent litigation, Gertjan also advises his clients on licensing (programs), IP strategy, and IP structuring in contract research and joint (private/private and public/private) R&D. He, for example, advised the Dutch Polymer Institute (a foundation funded by international industry, universities and government) as well as the TTI Green Genetics on their IP policy and structure. In addition, he is often involved in IP matters in deals from De Brauw’s M&A and Finance practices, including transactions involving NXP.

Gertjan successfully defended KPN in a very high profile preliminary injunction case and proceedings on the merits brought by a ‘non-practising entity’ for alleged infringement of an essential patent in UMTS. And in late 2009, Gertjan obtained an injunction for Sharp Corporation in the Dutch arm of a worldwide patent dispute with Samsung on LCD panel technology. Specialist journal Intellectual Asset Management ranks Gertjan among the world's 250 leading patent lawyers.

Gertjan lectures on patent law at universities and to IP practitioners-in-training and is a contributor to the patent section of the Elsevier loose-leaf commentary on IP. He is furthermore a country respondent for the Bio Science Law Review.

Gertjan is an active member of several national and international professional associations including AIPPI, EPLAW and the European Practice Committee of IPO.

Gertjan is an alumnus of the Fulbright Program.